Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual Meeting

Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual Meeting

Long-term follow-up shows all patients who demonstrated sustained disability improvement (SDI) maintained it at all subsequent timepoints

50 percent of patients in the two highest dose Cohorts (3 and 4) demonstrated SDI at 15 months

Cohort 4 dose selected for the ongoing randomized placebo-controlled clinical trial (RCT) based on higher proportion of patients showing sustained EDSS improvements and consistent safety profile over 15 months

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will present for the first time 15-month safety and efficacy data from all patients in the two highest dose cohorts of the Phase 1a open-label extension (OLE) study of ATA188 for the treatment of progressive forms of multiple sclerosis (MS). The results are featured in a poster presentation at the European Charcot Foundation (ECF) 28th Annual Meeting, held November 15-19, 2020.

“We are very pleased to see dose-related and durable responses maintained long-term which likely indicate a treatment effect with ATA188,” said Jakob Dupont, Global Head, Research and Development at Atara. “Seeing 50 percent of patients achieve long-term sustained disability improvement out to 15 months is remarkable in progressive forms of MS and supports the continued clinical investigation of ATA188 for this devastating disease for which there are currently no treatment options that substantially alter the course of disease.”

Findings presented include data on 24 patients from the 12-month dose escalation portion of the trial, 16 of whom entered the OLE and have ≥15-month data available as of October 2020. Throughout the entire Phase 1a and OLE study, nine of the 16 patients who entered the OLE demonstrated sustained disability improvement (SDI) with ATA188 treatment (seven achieved SDI in the first twelve months and two during the OLE). In seven out of the nine patients, SDI was driven by sustained improvement in Expanded Disability Status Score (EDSS).

A dose-related increase in the number of patients meeting SDI criteria was observed. Similar safety profile with no dose-limiting toxicities was shown in the highest dose cohorts (Cohorts 3 and 4). In the two highest dose cohorts, five out of 12 total patients (42%) and six out of 12 total patients (50%) demonstrated SDI at 12 and 15 months, respectively. SDI was driven by EDSS in all but one of the patients in Cohorts 3 and 4; all SDI observed in Cohort 4 was based on EDSS improvement. The Cohort 3 and 4 doses demonstrated similar efficacy profile based on SDI, with the Cohort 4 dose trending toward greater effect on EDSS.

Given encouraging clinical results to date in ATA188 studies and the significant unmet medical need in progressive forms of MS, the Company is increasing its investment in the ATA188 program. Atara is expanding the size of the RCT to at least 64 patients, changing the primary endpoint of the study to disability improvement, and maintaining biological and functional endpoints.

“With a higher proportion of patients demonstrating sustained EDSS improvements and a continued favorable safety profile, we will start treating newly enrolled patients with the Cohort 4 dose per the amended protocol in the randomized placebo-controlled study,” said AJ Joshi, M.D., Senior Vice President and Chief Medical Officer of Atara Biotherapeutics. “Additionally, we are making great progress enrolling the randomized trial and advancing the overall development program. We look forward to continuing to periodically provide meaningful data updates from the OLE.”

The Company recently submitted material to the U.S. Food and Drug Administration (FDA), that includes the Phase 1a data, planned updated design of the RCT and discussion of potential opportunities for expedited development of ATA188 for patients living with progressive forms of MS. Feedback from the agency is expected at the end of 2020.

About ATA188

Epstein-Barr Virus (EBV) is associated with a wide range of hematologic malignancies and solid tumors, as well as certain autoimmune conditions such as multiple sclerosis (MS). T cells are a critical component of the body’s immune system and can selectively target EBV believed to be important in the pathogenesis of MS.

Off-the-shelf, investigational ATA188, has the potential to target EBV-infected B cells and plasma cells in the central nervous system that may catalyze autoimmune responses and MS pathophysiology.

Atara is advancing the clinical development of ATA188 with a double-blind, randomized, placebo-controlled clinical trial (RCT) in patients with progressive MS across clinical sites in the U.S. and Australia. In addition to measuring disability progression, the study will also evaluate many facets of the disease, including: cognition and outpatient ambulatory activity; fatigue, and biological end points in blood and cerebrospinal fluid/CSF (IgG, synthesis and index, OCBs, product kinetics); and MRI imaging.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains or may imply “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: the potential benefits, safety and efficacy of ATA188; data from the Phase 1a study of ATA188; planned updates to the design of the ATA188 RCT; the timing and progress of clinical trials of ATA188, and Atara’s ability to successfully advance the development of ATA188. Because such statements deal with future events and are based on Atara Biotherapeutics’ current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara Biotherapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Atara’s cash resources and need for additional capital; and other risks and uncertainties affecting Atara’s and its development programs, including those discussed in Atara Biotherapeutics’ filings with the Securities and Exchange Commission (SEC), including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara Biotherapeutics disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

INVESTOR & MEDIA:

Media

Kerry Beth Daly

Head, Corporate Communications

Atara Biotherapeutics

516-982-9328

[email protected]

Investors

Eric Hyllengren

Vice President, Investor Relations & Finance

Atara Biotherapeutics

805-395-9669

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Health Clinical Trials Research Pharmaceutical Science Biotechnology

MEDIA:

Logo
Logo

RAPT Therapeutics to Announce Initial Data from Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2020 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that the Company plans to present initial data from its Phase 1/2 clinical trial of FLX475 in patients with multiple cancer indications in a premarket press release and webcast on Monday, November 16, 2020.

RAPT will host a conference call accompanied by a slide presentation at 8:30 a.m. ET on Monday, November 16th. The live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations. The call can be accessed by dialing (833) 672-0665 (domestic) or (929) 517-0344 (international) and refer to conference ID 6772479. The webcast will be available for replay for two weeks. Please connect to the website 10 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

About RAPT Therapeutics, Inc.

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including hematopoietic progenitor kinase 1 (HPK1) and general control nonderepressible 2 (GCN2), that are in the discovery stage of development.

RAPT
Media Contact:

Angela Bitting
[email protected]
(925) 202-6211

RAPT
Investor Contact:

Sylvia Wheeler
[email protected]



SIGMA America Reveals Black Friday Pricing on Popular Lenses and Accessories

RONKONKOMA, N.Y., Nov. 15, 2020 (GLOBE NEWSWIRE) — SIGMA Corporation of America has announced limited-time Black Friday pricing on a variety of popular photography products from Sunday, November 15 through Monday, December 7, 2020 at SIGMA Authorized Dealers in the United States. SIGMA is also offering a Zero Percent Financing option for Cine lens purchases, currently available through the end of 2020, as well as discounts on purchases of multiple Cine lenses.

For the first time ever, SIGMA America will offer Instant Savings on both the acclaimed 24-70mm F2.8 DG OS HSM | Art zoom lens and the mirrorless-exclusive 24-70mm F2.8 DG DN | Art. In addition, SIGMA’s most popular Art prime lenses – the 35mm F1.4 DG HSM | Art, 50mm F1.4 DG HSM | Art and 85mm F1.4 DG HSM | Art – will feature savings for a limited time, making some of the most desirable lenses in the SIGMA Art line more accessible to photographers than ever before.

SIGMA
Black Friday Instant Savings (Nov. 15 – Dec. 7, 2020)

24-70mm F2.8 DG DN | Art – Versatile design without compromise.
$40 Savings / Price: $1,059

24-70mm F2.8 DG OS HSM | Art – The leading lens for every moment.
$240 Savings / Price: $1,059

18-35mm F1.8 DC HSM | Art – The first and fastest of its kind.
$120 Savings / Price: $679

24-105mm F4 DG OS HSM | Art – A workhorse lens.
$100 Savings / Price: $799

35mm F1.4 DG HSM | Art – The original Art lens.
$200 Savings / Price: $699

50mm F1.4 DG HSM | Art – The Art standard.
$150 Savings / Price: $799

85mm F1.4 DG HSM | Art – Impeccable portraiture.
$150 Savings / Price: $1,049

70-200mm F2.8 DG OS HSM | Sports – Lightweight, perfect for on the move.
$160 Savings / Price: $1,339

16mm F1.4 DC DN | Contemporary – The versatile prime.
$50 Savings / Price: $399

30mm F1.4 DC DN | Contemporary – Blend of compact and quality.
$50 Savings / Price: $289

45mm F2.8 DG DN | Contemporary – Balanced performance and size.
$100 Savings / Price: $449

56mm F1.4 DC DN | Contemporary – A high-precision mid-tele.
$50 Savings / Price: $429

Mount Converter MC-11 – SIGMA quality, Sony capability.
$100 Savings / Price: $149

Mount Converter MC-21 – Stay flexible with L-mount lens access.
$100 Savings / Price: $149

A number of additional SIGMA photo products – including the SIGMA fp full-frame digital camera, all-in-one 18-300mm DC Macro OS HSM | Contemporary, ultra-close focusing 105mm F2.8 EX DG OS HSM Macro, and both versions of the stellar 150-600mm DG OS HSM telephoto zoom – will offer ongoing Instant Savings through the end of November.

SIGMA Cine Lens Offers

Filmmakers can also take advantage of SIGMA’s recently announced Zero Percent Financing option when making an investment in Cine lenses. When purchasing Cine lenses from an authorized SIGMA Cine dealer, buyers can apply for financing with available terms of 12 Months (0%), 24 months (2.49%) or 36 months (3.9%). This promotion is currently available through December 31, 2020.

In addition, while pre-made Cine lens kits have always come with a discount, SIGMA is now offering the option to pick specific lenses for specific needs with “Build Your Own” lens kit discounts up to 15% off retail price.

  • 3 – 4 prime Cine lenses = 5% off
  • 5 – 7 prime Cine lenses = 7% off
  • 8 – 9 prime Cine lenses = 10% off
  • All 10 prime Cine lenses = 15% off

Links

Visit sigmaphoto.com/black-friday for all SIGMA Black Friday Instant Savings.

Visit sigmaphoto.com/lenses/instant-savings for Instant Savings on all eligible SIGMA products.

Visit sigmaphoto.com/zero-percent-financing for more about 0% Financing on SIGMA Cine lenses.

Visit sigmaphoto.com/cine/cine-lens-sets for more about “Build Your Own” Cine lens kit discounts.

About Sigma America

Craftsmanship. Precision. Dedication. Since 1961, SIGMA has been devoted to the pursuit of advancing photographic technology. Unique to the industry, the family-owned business produces its high-quality, award-winning still photo and cinema camera lenses, DSLR and mirrorless cameras, flashes, filters and accessories from its state-of-the-art manufacturing facility located in Aizu, Japan.

In 2012, the company introduced SIGMA Global Vision with three distinct lens lines: Art, Contemporary and Sports. Designed for industry camera mount systems including Canon, Leica, Nikon, Olympus, Panasonic, Sony and Sigma, each lens is handcrafted and tested in Japan to ensure a high-performance, premium product that is purpose-built to last. In 2016, the SIGMA Cine lens lineup was launched, further cementing SIGMA as an innovator in imaging engineering. Embodying the core optical DNA that has defined the SIGMA benchmark of excellence, SIGMA cine lenses meet the needs of advanced 6k and 8k cinema production.

Forming the landmark L-Mount alliance alongside Leica and Panasonic in 2018, SIGMA continues its storied tradition of imaging excellence through groundbreaking innovations such as the native L-mount SIGMA fp full-frame mirrorless digital camera, announced in July 2019. The introduction of the fp along with the availability of 20 award-winning SIGMA Global Vision lenses in native L-Mount format demonstrates SIGMA’s continued commitment to the creative community through expanded product offerings. With the fp and these lenses, even more shooters can now leverage SIGMA’s renowned optical formula to achieve their creative vision with ease.

For information about SIGMA America, please visit sigmaphoto.com and SIGMA Blog for helpful information about our products.

Follow SIGMA America on social media:

SIGMA Photo: Facebook, Twitter and Instagram.

SIGMA Cine: Facebook, Twitter and Instagram.

Jack Howard / SIGMA Corporation of America / [email protected]

Photos accompanying this announcement are available at: 

https://www.globenewswire.com/NewsRoom/AttachmentNg/a870dfb1-5643-4200-9136-98afbb8e5d11

https://www.globenewswire.com/NewsRoom/AttachmentNg/58e8e370-443d-4e89-b6ca-68a02c10e0f2



NIKOLA 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Nikola Corporation – NKLA, NKLAW, f/k/a VectoIQ Acquisition Corp. VTIQ, VTIQW, VTIQU

NIKOLA 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Nikola Corporation – NKLA, NKLAW, f/k/a VectoIQ Acquisition Corp. VTIQ, VTIQW, VTIQU

NEW ORLEANS–(BUSINESS WIRE)–
ClaimsFiler, a FREE shareholder information service, reminds investors that they have only untilNovember 16, 2020 to file lead plaintiff applications in securities class action lawsuits against Nikola Corporation (NasdaqGS: NKLA, NKLAW) f/k/a VectoIQ Acquisition Corp. (NasdaqCM: VTIQ, VTIQW, VTIQU), if they purchased the Company’s securities between March 3, 2020 and October 15, 2020, inclusive (the “Class Period”) or owned VectoIQ shares as of the May 8, 2020 record date and were entitled to vote on VectoIQ’s proposed transaction with Nikola. These actions are pending in the United States District Courts for the District of Arizona, Eastern District of New York and Central District of California.

Get Help

Nikola investors should visit us at https://www.claimsfiler.com/cases/view-nikola-corporation-securities-litigation or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuits

Nikola and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On September 10, 2020, Hindenburg Research published a report alleging that evidence showed the Company was “an intricate fraud built on dozens of lies.” Subsequently, it was reported that the Company was the subject of probes by both the U.S. Securities and Exchange Commission and the Justice Department. Then, on September 21, 2020, the Company announced the sudden resignation of Founder and Executive Chairman, Trevor Milton. Then, in several interviews on October 15-16, 2020, the Company’s CEO made statements indicating that the Company’s strategic manufacturing partnership with General Motors could fall through.

On this news, the price of Nikola’s shares plummeted.

The first-filed case is Borteanu v. Nikola Corporation et al., 20-cv-01797.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

ClaimsFiler

Lewis Kahn, 844-367-9658

https://www.claimsfiler.com

KEYWORDS: United States North America Louisiana

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Pomerantz Law Firm Announces the Filing of a Class Action against Wells Fargo & Company and Certain Officers — WFC

PR Newswire

NEW YORK, Nov. 14, 2020 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Wells Fargo & Company (“Wells Fargo” or the “Company”) (NYSE: WFC) and certain of its officers.   The class action, filed in United States District Court for the Northern District of California and docketed under 20-cv-07997, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Wells Fargo securities between October 13, 2017 and October 13, 2020, inclusive (the “Class Period”).  Plaintiff seeks to pursue remedies against Wells Fargo and certain of the Company’s current and former senior executives under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Wells Fargo securities during the Class Period, you have until December 29, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 


[Click here for information about joining the class action]
 

Wells Fargo is a global financial services company headquartered in San Francisco, California.  The Company provides banking, investment and mortgage products and services, as well as other consumer and commercial financial services.  It is one of the largest banks in the world as measured by both market capitalization and total assets.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Wells Fargo had systematically failed to follow appropriate underwriting standards and due diligence guidelines in issuing billions of dollars’ worth of commercial loans, including by inflating the net income and future expected cash flows of its commercial clients to justify issuing excessive loan amounts; (ii) a materially higher proportion of Wells Fargo’s commercial loan customers were of poor credit quality and/or at a substantially higher risk of default than disclosed to investors; (iii) Wells Fargo had failed to timely write down commercial loans, collateralized loan obligations (“CLOs”) and commercial mortgage backed securities (“CMBS”) on its books that had suffered impairments; (iv) Wells Fargo had materially understated the reserves needed for expected credit losses in its commercial portfolios; (v) Wells Fargo had systematically misrepresented the credit quality and likelihood of default of the loans it packaged and securitized into CLOs and CMBS, including by artificially inflating the net income and expected cash flows of its commercial clients in loan and securitization documentation; (vi) the CLO and CMBS-related loans issued and investment securities held by Wells Fargo were of lower credit quality and worth far less than represented to investors; (vii) as a result of (i)-(vi) above, Wells Fargo’s Class Period statements regarding the credit quality of its commercial loans, its underwriting and due diligence practices, and the value of its CLO and CMBS books were materially false and misleading; and (viii) as a result of all the foregoing, Wells Fargo was exposed to severe undisclosed risks of financial, reputational and legal harm, in particular in the event of significant and sustained stress in the commercial credit markets.

On April 14, 2020, Wells Fargo issued a press release providing its results for the first quarter of 2020.  The release revealed a stunning deterioration in the Company’s credit portfolio, particularly with respect to its commercial loans.

On this news, Wells Fargo’s stock price fell 14% over the following three trading sessions, closing at $26.89 per share on April 16, 2020.

Then, on May 5, 2020, Wells Fargo filed its quarterly report for the first quarter with the SEC, which stated that the fair value of the Company’s CLO investments held-for-sale had fallen to $26.9 billion by the quarter’s end, a 9% decline from the end of the quarter and year ended December 31, 2019 (“FY19”), and that Wells Fargo had suffered $1.7 billion in unrealized losses on its CLO investments during the quarter.

On this news, Wells Fargo’s stock price fell another 6% over two trading days to close at $25.61 per share on May 6, 2020.

Then, on June 10, 2020, Wells Fargo’s Chief Financial Officer John Shrewsberry (“Shrewsberry”) presented at the Morgan Stanley Virtual US Financials Conference.  During the conference, Shrewsberry revealed that Wells Fargo’s second quarter reserve build would be even “bigger than the first quarter” as a result of continued deterioration in the Company’s credit portfolio. 

On this news, Wells Fargo’s stock price fell 18% over two trading days to close at $26.79 per share on June 11, 2020.

On July 14, 2020, Wells Fargo issued a release providing its results for the second quarter of 2020.  The release stated that Wells Fargo had suffered a $2.4 billion loss during the quarter, or ($0.66) per share, largely as a result of deterioration in its commercial credit portfolio.

On this news, Wells Fargo’s stock price fell another 5% to close at $24.25 per share on July 14, 2020. 

Finally, on October 14, 2020, Wells Fargo issued a release providing its results for the third quarter of 2020.  The release stated that Wells Fargo had recognized another provision expense of $769 million and that non-accrual loans had increased $2.5 billion, or 45%, to $8 billion during the quarter.

On this news, Wells Fargo’s stock price fell another 6% to close at $23.25 per share on October 14, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected] 
888-476-6529 ext. 7980

Cision View original content:http://www.prnewswire.com/news-releases/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-wells-fargo–company-and-certain-officers—-wfc-301173156.html

SOURCE Pomerantz LLP

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Nikola (NKLA) Investors to Monday Application Deadline, Investors with $500k+ Losses Should Contact the Firm

SAN FRANCISCO, Nov. 14, 2020 (GLOBE NEWSWIRE) — Hagens Berman urges Nikola Corporation (NASDAQ: NKLA) investors to contact the firm now. A securities fraud class action has been filed and NKLA investors may have sufficient losses to move for lead plaintiff.

Class
Period: Mar. 3, 2020 – Sept. 20, 2020
Lead Plaintiff Deadline: Nov. 16, 2020
Visit:www.hbsslaw.com/investor-fraud/NKLA
Contact An Attorney Now:[email protected]
844-9160895

Nikola Corporation
(
NKLA
)
Securities Class Action:

The Complaint alleges that throughout the Class Period, Defendants falsely stated or omitted, among other things, that: (1) Nikola overstated its in-house design, manufacturing, and testing capabilities; (2) exaggerated its hydrogen production capabilities; (3) as a result, Nikola overstated its ability to lower the cost of hydrogen fuel; (4) Nikola founder and Executive Chairman, Trevor Milton, tweeted a misleading test video of the Company’s Nikola Two truck; (5) the work experience and background of key Nikola employees, including Mr. Milton, had been overstated and obfuscated; and (6) Nikola did not have five Tre trucks completed.

Investors learned the truth through a series of partial disclosures, beginning on Sept. 10, 2020, when Hindenburg Research published a scathing report accusing Nikola of lying about its truck’s capabilities, partnerships and products, and ending on Sept. 20, 2020, when Milton abruptly resigned.

These events have driven the price of Nikola shares sharply lower.

Significantly, less than a month before these disclosures, on Aug. 11, 2020, In-Cap, an entity indirectly controlled by Nikola director Jeffrey Ubben, sold 1.4 million Nikola shares at $42.69/share for a total of over $59 million. While Ubben reportedly contends the suspiciously timed sale was forced on him by “investor redemptions,” Hagens Berman is actively investigating the validity of this claim.

On Sept. 29, 2020 CNBC reported a second sexual abuse allegation against Milton and that the widely-touted partnership with GM announced earlier in the month is not a “done deal.”

Most recently, on Nov. 9, 2020, Nikola revealed that during Sept. 2020 the SEC and two grand juries served subpoenas on the Company, Milton, and other officers, all of which are related to Hindenburg’s findings on the Company.

“We’re focused on (i) investors’ losses, (ii) proving Nikola misrepresented its truck’s functionality, its technology and partnerships, and (iii) whether Nikola stakeholders like Ubben engaged in unlawful insider trading,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you are a Nikola investor or may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Nikola should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 8449160895 or email [email protected].


About Hagens Berman


Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation.   More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact
:

Reed Kathrein, 844-916-0895



Hyundai Mobis Hires Former Valeo Executive Committee Member as Head of Global Sales for International Expansion

– Axel J. Maschka becomes Executive VP for the company, reporting to CEO

– Served as former Senior VP at Valeo, Volvo, Bosch, Continental, and etc

– First non-Korean C-Level executive with 30+ years of experience, expecting growth of global sales

PR Newswire

SEOUL, South Korea, Nov. 14, 2020 /PRNewswire/ — Hyundai Mobis (KRX: 012330) announced on 15th that the company has hired executive vice president, Axel J. Maschka as head of the Global Sales Division. Previously Mr. Maschka served as a senior VP and Executive Committee member at Valeo in charge of Sales and Business Development.

Mr. Maschka has spent 30 years in the automotive industry after graduating from the University of Stuttgart in electrical engineering including a two years tenure at Telecom Paris Tech. German native, Mr. Maschka has worked in various automakers and suppliers including, Volvo, Mercedes-Benz, Bosch, and Continental. Recently, in France, he served as a founder and CEO at AMA-ADVISORS, a consulting firm to represent the new scope towards the e-mobility transition. 

Hyundai Mobis is known to have set a high value on his outstanding management performance and his ability to understand global markets. Mr. Maschka also contributed as a BOD and Steering Committee member at CLEPA, the European Automotive Supplier Association.

In his new role as head of global sales in Hyundai Mobis, Mr. Maschka will lead and expand the division to receive orders from European, North American, and Chinese automakers by taking advantage of the current transformation of the automobile industry towards connected autonomous and electric vehicles. Hyundai Mobis, global No.7 parts suppliers, has been continuously increasing sales from non-Hyundai/Kia automakers.

Meanwhile, Mr. Maschka is the first non-Korean executive to be hired by Hyundai Mobis in the non-R&D area. In addition he is the highest-ranking foreign executive, level C, and will directly report to CEO of Hyundai Mobis.

About Hyundai Mobis

Hyundai Mobis is the 7th largest leading automotive supplier. Founded in 1977 and is headquartered in Seoul, Korea, Hyundai Mobis is to become a lifelong technology partner for vehicles and people.

Hyundai Mobis is excellent in sensors, sensor fusion in controllers and software design capabilities in safety control. Its products also include various electrification components, brakes, suspension, steering, airbags, lights and automotive electronics.

Mobis currently has more than 30,000 employees and has been manufacturing in more than 30 regions in 10 countries. In addition to its R&D headquarters in Korea, Mobis has 4 technology centers in Germany, China, India and the United States.

Media Contact

Jihyun Han (+82-2-2018-6026, [email protected])  
Choon Kee Hwang (+82-2-2018-5519, [email protected])  

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hyundai-mobis-hires-former-valeo-executive-committee-member-as-head-of-global-sales-for-international-expansion-301172725.html

SOURCE Hyundai Mobis

Is the blazing Canadian housing market just all smoke? Don’t get lured into the hype! The Real Estate Investment Network report weighs in

All smoke, no fire – Despite appearances, Canadian housing markets fall further into slump, based on underlying economic fundamentals

Vancouver, BC, Nov. 14, 2020 (GLOBE NEWSWIRE) — Contrary to a growing number of real estate market predictions, a new report by The Real Estate Investment Network suggests housing markets are falling deeper into slump despite increasing property prices.

According to The Real Estate Investment Network’s COVID-19 Special Edition: Real Estate Cycle Update report, all major real estate markets in British Columbia, Alberta, and Ontario have fallen further into the real estate slump phase driven mainly by the economic impacts of the COVID-19 pandemic.

These findings are based on many research methodologies including The Real Estate Investment Network’s Economic Turmoil Formula and Real Estate Cycle Scorecard. Both resources highlight rapidly evolving changes of the underpinning economic fundamentals affecting real estate markets, such as GDP, employment, and population. The report indicates the continued impact of COVID-19 on these driving indicators has moved most markets further into the slump phase.

The Real Estate Investment Network’s COVID-19 Special Edition: Real Estate Cycle Update produced real estate cycles for three provinces:

  • British Columbia – Beginning of slump
  • Alberta – Beginning to middle of slump
  • Ontario – Beginning of slump

As well as five major cities:

  • Vancouver – Beginning of slump
  • Calgary – Beginning to middle of slump
  • Edmonton – Beginning to middle of slump
  • Toronto – Beginning of slump
  • Ottawa – Beginning of slump

While others suggest hot markets in major Canadian cities, The Real Estate Investment Network research shows these may all turn out to be just hype.  

“At first glance, it might look like the data is pointing towards a market boom because in many key cities, real estate values have been, and continue to, increase. But this is all smoke and no fire. This is is a common misconception since characteristics of the boom and slump phases of the real estate cycle sometimes overlap and can be confusing to many if not most people,” explains Jennifer Hunt, Vice President Research, The Real Estate Investment Network. “When looking ahead, the signals indicate markets are further entrenched in the early phases of the slump, so homebuyers and investors are wise to proceed with caution.”

The real estate cycle functions as a predictive tool to determine which phase a specific market is currently in based on driving indicators and market influencers. The report shows where specific markets are at in the real estate cycle including which investment tactics are best suited for each phase.

“It’s common to have rising real estate prices in the early stages of the slump phase. Even while prices in many markets are still rising, prices are not the only indicator. Most other data are now pointing at a slump,” added Hunt.

The report includes a new and expanded tactics table (of what to do and what to avoid during various phases of the cycle) featuring a total of 11 tactics:

  1. Buy and Hold
  2. Rent to Own
  3. Fix and Flip
  4. Fix, Flip, Refinance
  5. Agreement for Sale (Buy)
  6. Agreement for Sale (Sell)
  7. Option to Purchase (Entrance)
  8. Assignment
  9. Foreclosure (Availability)
  10. Vendor Take Back (Buy)
  11. Vendor Take Back (Sell)

According to Hunt, the new tactics table is meant to guide investors on how to respond to specific market conditions.

“Regardless of current market conditions, there are always good options available for real estate investors in every phase of the real estate cycle. What’s more important is to stay ahead of the curve, don’t get caught up by the hype, and quickly adapt to what the market gives you. It’s like making lemonade out of lemons. For example, when life gives you a market slump, towards the end is the optimal time to buy-and-hold, but now it’s early, so prepare for the end phase of the slump and ensure you invest wisely ” Hunt added.  

About The Real Estate Investment Network

The Real Estate Investment Network is the sum of numerous parts. Founded in 1992, it has since been the most trusted, unbiased real estate investing resource for education, research, and investment strategies.

For over 28 years, The Real Estate Investment Network has been at the forefront to change the conversation about real estate investing. A vigorous combination of meticulous research and analysis, brass tack economic fundamentals, strategic investing systems, exceptional market specialists, and solid industry leaders all contribute to world class, relevant education and development, accessible to all real estate investors.

The dynamic and noteworthy team at The Real Estate Investment Network is a collective of game changers, empowering leaders, and successful entrepreneurs. Together, they collaborate with purpose to advance the community experience for new investors and seasoned professionals alike.

Decades of hands-on experience and real estate investing analysis allows them to effectively create and support an environment for investors to thrive in their business of real estate investing and achieve their financial security and certainty. You can count on The Real Estate Investment Network Team to deliver relevant, authentic, and meaningful resources, always with commitment and intention for an exceptional Member experience.

 

For more information:  

You may access a copy of the report here



Jennifer Hunt
The Real Estate Investment Network
604-449-6034
[email protected]

ROSEN, TOP RANKED INVESTOR COUNSEL, Reminds Turquoise Hill Resources Ltd. Investors of Important December 14 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – TRQ

PR Newswire

NEW YORK, Nov. 14, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Turquoise Hill Resources Ltd. (NYSE: TRQ) between July 17, 2018 and July 31, 2019, inclusive (the “Class Period”), of the important December 14, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Turquoise Hill investors under the federal securities laws.

To join the Turquoise Hill class action, go to http://www.rosenlegal.com/cases-register-1971.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, throughout the Class Period and regarding the development of the Oyu Tolgoi copper-gold mine in Mongolia, defendants made false and/or misleading statements and/or failed to disclose that: (1) the stability issues were much more severe than represented and called into question the design of the mine, the projected cost and timing of production; (2) the publicly disclosed estimates of the cost, date of completion and dates for production from the underground mine were not achievable; (3) the “challenging ground conditions” were much more severe than defendants represented, and in fact made it impossible for Turquoise Hill and Rio Tinto to achieve those estimates; (4) the development capital required for the underground development of Oyu Tolgoi would cost substantially more than a billion dollars over what Turquoise Hill and Rio Tinto had represented; (5) Turquoise Hill would require additional financing and/or equity to complete the project; (6) the progress of underground development and of Oyu Tolgoi was not proceeding as planned; and (7) the “key risks” had not been “well understood and managed” but had placed the project schedule and cost into severe jeopardy. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 14, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1971.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-top-ranked-investor-counsel-reminds-turquoise-hill-resources-ltd-investors-of-important-december-14-deadline-in-securities-class-action-encourages-investors-with-losses-in-excess-of-100k-to-contact-firm–trq-301173140.html

SOURCE Rosen Law Firm, P.A.

Hot Wheels®Legends Tour Winner Announced During Finale Event at Jay Leno’s Garage: Custom Car Joins Hot Wheels®Collection as 1:64-scale Die-Cast Vehicle

Hot Wheels®Legends Tour Winner Announced During Finale Event at Jay Leno’s Garage: Custom Car Joins Hot Wheels®Collection as 1:64-scale Die-Cast Vehicle

  • The 1970 Pontiac Trans Am is named the winner of the Hot Wheels Legends Tour, the world’s largest international traveling car show
  • The global search for the next Hot Wheels die-cast culminated at the iconic Jay Leno’s Garage after a historic series of virtual car shows

EL SEGUNDO, Calif.–(BUSINESS WIRE)–
Mattel (NASDAQ: MAT) announced today the winner of the 2020 Hot Wheels Legends Tour. The 1970 Pontiac Trans Am custom car, built by Riley Stair of Sacramento, will be inducted into the Hot Wheels Garage of Legends and will join the Hot Wheels collection as a 1:64 scale die-cast. The 1970 Pontiac Trans Am is the third fan’s car to become a Hot Wheels die-cast and will hit store shelves worldwide in 2021. The announcement was made during the Hot Wheels Legends Tour Finale event by Ted Wu, Vice President of Global Design for Vehicles at Mattel.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201114005121/en/

The 1970 Pontiac Trans Am is named the winner of the Hot Wheels Legends Tour, the world's largest international traveling car show (Photo: Business Wire)

The 1970 Pontiac Trans Am is named the winner of the Hot Wheels Legends Tour, the world’s largest international traveling car show (Photo: Business Wire)

The final stop was live-streamed from Jay Leno’s Garage and co-hosted by Jay Leno and motorsports ambassador Jarod DeAnda. Viewers tuned into Jay Leno’s Garage YouTube Page and Hot Wheels’ Facebook Page to see the winner determined by Hot Wheels designers and car-loving celebrity judges Jay Leno, Snoop Dogg, Gabriel ‘Fluffy’ Iglesias and Brionna Lynch. Special guests including 007 driver Ben Collins, Paxton Booth and NASCAR driver Tony Stewart also participated in the event.

Riley Stair’s build was chosen from thousands of cars entered in the Hot Wheels Legends Tour, which had 14 stops throughout Europe, LATAM, Asia and North America. While all finalists who competed at the global finale event embodied Hot Wheels high standards or performance and design, the winning custom build was selected for its true representation of the Hot Wheels garage spirit.

“By going virtual, the third year of the Hot Wheels Legends Tour demonstrated tremendous growth, engaging over 10 million fans from around the world,” said Ted Wu, Vice President, Global Head of Design for Vehicles, Mattel. “With more vehicle entries this year than ever before, we know we found a special build that embodies the Hot Wheels challenger spirit with the 1970 Pontiac Trans Am. You see the vehicle and instantly know it is meant to be a Hot Wheels with the unique frame, engine, and purpose-driven build.”

The 1970 Pontiac Trans Am is a one of a kind race car engineered by Riley Stair on the side of his parents’ house. Revving up to 10,000 RPM, the vehicles motor is entirely custom built, and the foundation for the engine is a 400-cubic inch LS V8.

“To have my car immortalized as a Hot Wheels die-cast for car lovers of all ages to enjoy means the world to me,” said Legends Tour Winner Riley Stair. “To think that my car in a 1:64 scale could make a lasting impression for a young kid who loves cars, as Hot Wheels have for so many of us, is a dream come true. I can’t wait to see my nephew Noah pushing my car around the living room!”

A team of judges, including Hot Wheels designers, celebrities and automotive influencers, chose the Legends Tour winner for its authenticity, originality and garage spirit. The Legends Tour winner’s life-size car and die-cast version will also join the Hot Wheels Garage of Legends, a collection of one-of-a-kind cars immortalized as Hot Wheels die-casts that meet the brand’s high benchmarks of style and performance.

The Hot Wheels Legends Tour Finale event was made possible in partnership with Mobil 1, Walmart, Ford, American Pinball, Hagerty and Horizon Brands. To learn more about the Hot Wheels Legends Tour visit https://hotwheels.mattel.com/explore/en/legends-tour# and follow #HotWheelsLegends.

About Mattel

Mattel is a leading global toy company and owner of one of the strongest catalogs of children’s and family entertainment franchises in the world. We create innovative products and experiences that inspire, entertain and develop children through play. We engage consumers through our portfolio of iconic brands, including Barbie®, Hot Wheels®, Fisher-Price®, American Girl®, Thomas & Friends™, UNO® and MEGA®, as well as other popular intellectual properties that we own or license in partnership with global entertainment companies. Our offerings include film and television content, gaming, music and live events. We operate in 35 locations and our products are available in more than 150 countries in collaboration with the world’s leading retail and e-commerce companies. Since its founding in 1945, Mattel is proud to be a trusted partner in empowering children to explore the wonder of childhood and reach their full potential.

MAT-CORP

Scott Shaffstall

Mattel Global Communications

[email protected]

310-252-3610

Michelle Neumayr

Mattel Global Communications

[email protected]

650-215-8804

Natalie Hamlin

Weber Shandwick

[email protected]

276-732-1464

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Retail Automotive Consumer Department Stores Performance & Special Interest Children Specialty

MEDIA:

Photo
Photo
The 1970 Pontiac Trans Am is named the winner of the Hot Wheels Legends Tour, the world’s largest international traveling car show (Photo: Business Wire)